-
Product Insights
Delayed Graft Function (DGF) – Drugs In Development, 2023
Global Markets Direct’s, ‘Delayed Graft Function (DGF) - Drugs In Development, 2023’, provides an overview of the Delayed Graft Function (DGF) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Delayed Graft Function (DGF), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Ischemia Reperfusion Injury – Drugs In Development, 2023
Global Markets Direct’s, ‘Ischemia Reperfusion Injury - Drugs In Development, 2023’, provides an overview of the Ischemia Reperfusion Injury pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ischemia Reperfusion Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Traumatic Brain Injury – Drugs In Development, 2023
Global Markets Direct’s, ‘Traumatic Brain Injury - Drugs In Development, 2023’, provides an overview of the Traumatic Brain Injury pipeline landscape. The report provides comprehensive information on the therapeutics under development for Traumatic Brain Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CMX-2043 in Traumatic Brain Injury
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CMX-2043 in Traumatic Brain Injury report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.CMX-2043 in Traumatic Brain Injury Drug Details: CMX-2043 is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – CMX-2043
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry CMX-2043 Drug Details CMX-2043 is under development for the prevention of peri-operative cardiac ischemia-reperfusion...
-
Product Insights
Ischemia Reperfusion Injury Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Ischemic reperfusion injury is the tissue damage that happens when blood supply returns to the tissue after a period of lack of oxygen. The absence of oxygen and nutrients creates a condition in which the restoration of circulation results in inflammation and oxidative damage through the induction of oxidative. Symptoms include headache, bradycardia, seizures, and hypertension. Risk factors include hypertension, hyperlipidemia, diabetes, insulin resistance, heart failure, altered coronary circulation, and aging. The Ischemia Reperfusion Injury drugs in development market research...
-
Product Insights
Traumatic Brain Injury Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Traumatic brain injury happens when an external mechanical force causes brain damage. Traumatic brain injury usually results from a violent blow or jolt to the head or body. Symptoms include headache, dizziness, nausea or vomiting, mood changes, fatigue or drowsiness, difficulty sleeping, and memory or concentration problems. Risk factor includes age. Certain types of traumatic brain injury increase the risk of developing Alzheimer's disease and coordination problems. The traumatic brain injury drugs in development market research report provides an overview...
-
Product Insights
Contrast Induced Nephropathy Global Clinical Trials Review, H2, 2017
GlobalData's clinical trial report, “Contrast Induced Nephropathy Global Clinical Trials Review, H2, 2017" provides an overview of Contrast Induced Nephropathy clinical trials scenario. This report provides top line data relating to the clinical trials on Contrast Induced Nephropathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Product Insights
Ischemia Reperfusion Injury Global Clinical Trials Review, H2, 2017
GlobalData's clinical trial report, “Ischemia Reperfusion Injury Global Clinical Trials Review, H2, 2017" provides an overview of Ischemia Reperfusion Injury clinical trials scenario. This report provides top line data relating to the clinical trials on Ischemia Reperfusion Injury. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Product Insights
Contrast Induced Nephropathy Disease – Global Clinical Trials Review, H1 2019
GlobalData's clinical trial report, “Contrast Induced Nephropathy Global Clinical Trials Review, H1, 2019" provides an overview of Contrast Induced Nephropathy clinical trials scenario. This report provides top line data relating to the clinical trials on Contrast Induced Nephropathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...